Strides Pharma Science (NSE:STAR) Buyback Yield %: 0.00 (As of Jul. 04, 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
67 GF Score
Price ₹1,126.80
GF Value ₹776.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Buyback Yield %?

Strides Pharma Science NSE:STAR +0.04% 67 Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹776.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 292 Drug Manufacturers companies, Strides Pharma Science ranks worse than 342465.41% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Strides Pharma Science's current buyback yield was 0.00%.


Strides Pharma Science Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Buyback Yield % Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -3.24 -1.59 -0.10 0.00

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 0.00 0.00 0.00 0.00

NSE:STAR vs ZTS, UTHR: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Buyback Yield % falls into.


NSE:STAR
67GF Score
Strides Pharma Science Ltd NSE:STAR
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Strides Pharma Science's Buyback Yield for the fiscal year that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.86) / 86435.23075
=-0.00%

Strides Pharma Science's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 3.86) / 86435.23075
=-0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Strides Pharma Science (NSE:STAR) has a Buyback Yield % of 0.00 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Strides Pharma Science and its competitors. According to the industry distribution chart, Strides Pharma Science ranks #999999 out of 292 companies in the Drug Manufacturers industry.
Is Strides Pharma Science's Buyback Yield % too high?
Strides Pharma Science's current Buyback Yield % is 0.00. Based on the distribution chart, Strides Pharma Science ranks #999999 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #999999 out of 292 companies for Buyback Yield %. This places Strides Pharma Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹776.38, compared to a current price of ₹1,126.80 — trading 45.1% above its estimated fair value. The current Buyback Yield % is 0.00. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,126.80 is trading 45.1% above its estimated GF Value™ of ₹776.38. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Buyback Yield %: 0.00
  • GF Value™: ₹776.38 vs. price of ₹1,126.80 (45.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score

Get the complete analysis for NSE:STAR

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,126.80
Price
₹776.38
GF Value